Antineoplastics (BTK inhibitors)
- Block B-cell receptor signaling through BTK
- CLL + several B-cell malignancies
- Ibrutinib: effective but more off-target toxicity
- Acalabrutinib/zanubrutinib more selective
- Bleeding + atrial fibrillation are key issues
- CYP3A interactions can markedly alter exposure
- Infection + cytopenia risk persists
Class at a glance
- Block B-cell receptor signaling through BTK
Safety / monitoring
- Ibrutinib: effective but more off-target toxicity
- Acalabrutinib/zanubrutinib more selective
Pharmacology
- CYP3A interactions can markedly alter exposure
Practical pearls
- CLL + several B-cell malignancies
Safety distinctions
- Bleeding + atrial fibrillation are key issues
- Infection + cytopenia risk persists
Self-check
- What is the main pharmacologic action of Antineoplastics (BTK inhibitors)?
Block B-cell receptor signaling through BTK.
- What key adverse effect/risk occurs with Antineoplastics (BTK inhibitors)?
Bleeding + atrial fibrillation are key issues.
Drugs in this class (3)
All drug classes · Open the interactive console ↗
